Medtronic (NYSE: MDT), a global leader in healthcare technology, today announced the broad U.S. commercial launch of the MiniMed™ 780G system integrated with the Instinct sensor, made by Abbott and designed exclusively for MiniMed™ systems.
Following U.S. FDA clearance of the system earlier this year to enable integration with the Instinct sensor, the system is now shipping to customers across the U.S., marking a major milestone in diabetes technology and delivering a smart, seamless way to manage diabetes.
The Instinct sensor is based on Abbott’s most advanced CGM technology, featuring the world’s smallest1,2, thinnest1, most discreet2 sensor and offers a wear time of up to 15 days. When paired with the MiniMed™ 780G system, the Instinct sensor provides real-time glucose readings which the system uses to automate insulin adjustments every five minutes, helping people with diabetes spend less time managing their condition and more time living their life.
“Bringing together the Instinct sensor, made by Abbott, with the excellent algorithm of the MiniMed™ 780G system creates an extremely effective combination. With the MiniMed™ 780G system, my patients have seen improved time in range and now with the Instinct sensor it’s a seamless experience,” said Dr. Steve Edelman, a person living with type 1 diabetes and founder and director of Taking Control of Your Diabetes 501c3 (TCOYD.org). “Feedback from the early customer pilot program has been very positive and matches what my colleagues and I are seeing in our clinics. I’m thrilled that the Instinct sensor is now available so that more people living with type 1 diabetes will get access to this life-changing technology improving their day-to-day experience dealing with this difficult condition.”
The launch of the Instinct sensor expands Medtronic’s sensor portfolio, offering more choice alongside the recently launched Simplera Sync™ sensor and the Guardian™ 4 sensor—all part of a growing ecosystem designed to make diabetes care easier and more personalized.
“This milestone marks an important next step in our work to bring the proven clinical outcomes of our MiniMed™ 780G system to more people living with diabetes,” said Que Dallara, EVP and president of Medtronic Diabetes. “With this launch, we’re expanding a smart dosing ecosystem built for choice, so every person can find a solution that fits their life. We exist to make life with diabetes easier and more predictable, so people living with diabetes can enjoy greater freedom and better health every day. Our goal is to deliver confidence and peace of mind, so everyone—including loved ones—can live boldly without compromise.”